Alza Ditropan XL
Executive Summary
Promotional materials for the oxybutynin incontinence drug draws objection from FDA for "omission of material facts" and "overstatement of efficacy." FDA cites a direct-to-consumer letter for statements suggesting greater efficacy for Ditropan XL such as "Help take control...Simply, Confidently"; "Once-a-day confidence"; and"...you may be able to go where you want to go and do what you want - without the constant worry of finding a bathroom"